USMIRC News

🚨🔥 BIG NEWS | #ICETCongress 2026 🔥🚨 Get ready, Orlando! 🌴 📍 Orlando, FL 🗓 July 18, 2026 The National ICE-T Congress is back—bigger, bolder, and pushing the future of #CellTherapy forward 🚀 ⭐ Led by powerhouse chairs: @heMEGirl_MD @HemSandoval and our ICE-T Executive Director: @kczmj ⚡ CAR-T ⚡ Bispecifics ⚡ Real-world innovation ⚡ Multidisciplinary impact This is where the future of hematology meets action. Don’t miss it. @NausheenAhmedMD @KUcancercenter @USMIRCNEWS @oncodaily @MedwatchKate @US_HMC #MedEd #MedTwitter

Sharing highlights from today at the National Immune Cell Effector-Therapy Congress in Charlotte. Bispecifics are rapidly reshaping myeloma treatment, but any therapy is only as effective as access. Expanding access to the community is critical. Fantastic conference organized by @AtrashShebli Barry Paul @Abdallah81MD with great discussions. @oncodaily

National ICE-T Congress in Charlotte, NC #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS @CancerNetwrk

Dinner before we kick off the #ICETCongress tomorrow morning—@myelomadoctor @AtrashShebli Looking forward to an exciting meeting ahead! @oncodaily @MedwatchKate @USMIRCNEWS @US_HMC @KUcancercenter @Larvol

Hi friends, it's #Myeloma Monday! Here are Top Posts of the Week 🧵 1/ @Abdallah81MD on CAR-T resistance in myeloma: x.com/Abdallah81MD/s…

Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure #mmsm #USMIRC @USMIRCNEWS sciencedirect.com/science/articl…

Captured moments from The 4th International Myeloma Conference of Saudi Arabia brought together leading experts in a powerful hybrid experience a in Riyadh. 🇸🇦 #mmsm #myeloma #Medtwitter #USMIRC @Larvol @MedwatchKate @US_HMC @USMIRCNEWS @OncoAlert @KUHospital @KUcancercenter

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial #MedEd #MedTwitter #mmsm #myeloma #USMIRC @USMIRCNEWS sciencedirect.com/science/articl…

A 65-year-old patient with newly diagnosed multiple myeloma harboring high-risk cytogenetics t(4;14) received induction with daratumumab + RVd followed by ASCT At day +100 post-transplant, the patient achieves sCR/MRD - What is the most appropriate maintenance strategy?

Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib–Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis mdpi.com/3784382 #mdpicurroncol via @CurrentOncology @USMIRCNEWS @KUcancercenter

📍1/ Excited to share our latest publication in @CurrentOncology! We evaluated doublet maintenance (bortezomib + lenalidomide) vs. lenalidomide alone after ASCT in high-risk multiple myeloma, a multicenter analysis through @USMIRCNEWS. mdpi.com/1718-7729/33/3…

📍5/ Grateful to work on this project with Dr. Sruthi Ramanan, learn from the ground work of incredible @USMIRCNEWS collaborators @Abdallah81MD, and for the mentorship of Dr. Prerna Mewawalla @myelomadoctor on this publication! Read here: mdpi.com/1718-7729/33/3…

🚨 Save the Date! The National ICE-T Congress is coming to Orlando, Florida! 🗓 July 18, 2026 Led by outstanding chairs: Jose Sandoval-Sus, MD & Megan Melody, MD Driving innovation in cellular and T-cell–redirecting therapies. #mmsm #myeloma #MedEd #Medtiwitter #USMIRC @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @oncodaily

Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib–Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis #MedEd #medtwitter #mmsm #myeloma #USMIRC @USMIRCNEWS @US_HMC mdpi.com/1718-7729/33/3…

🧵 High-Risk Myeloma Maintenance 1️⃣🧬 Maintenance Strategies in High-Risk Multiple Myeloma (HRMM) New multicenter analysis from the USMIRC collaborative compares lenalidomide (R) vs bortezomib + lenalidomide (VR) maintenance after ASCT. Key question: 👉 Does intensifying maintenance improve outcomes in HRMM? #mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @Larvol @US_HMC @MedwatchKate @OncoAlert

Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib–Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis #mmsm #myeloma #USMIRC @USMIRCNEWS @US_HMC mdpi.com/1718-7729/33/3…

Exciting news ahead! Our team will be making a major announcement on April 18 at the ICE-T Congress in Charlotte, NC. Stay tuned. 🚀 #Myeloma #CellTherapy #ICETCongress #mmsm #myeloma @CancerNetwrk #USMIRC @USMIRCNEWS @MedwatchKate @Larvol @US_HMC #MedEd #medtwitter

Some major news in #myeloma @USMIRCNEWS @US_HMC #USMIRC #mmsm

Teclistamab in RRMM with Renal Impairment Real-world data from the USMIRC multi-institutional study 🧵 1️⃣🧬 (n=195) shows that teclistamab remains safe and effective even in patients with significant renal dysfunction (CrCl <40 mL/min) — a population excluded from the original MAJESTEC-1 trial. #mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @US_HMC @OncoAlert @MedwatchKate @Larvol

Honored to be inducted into the Gold Humanism Honor Society at the University of Kansas School of Medicine. Humanism in medicine begins with presence—listening, dignity, and compassion. Grateful to patients and colleagues at KUMC who teach these values every day. #HumanismInMedicine @KUMedicine @KUcancercenter